Fracture callus under anti-resorptive agent treatment evaluated by pQCT

Advanced Bioimaging Technologies in Assessment of the Quality of Bone and Scaffold Materials: Techniques and Applications

Volumn , Issue , 2007, Pages 553-566

  Cao, Yong Ping ^a   Mori, Satoshi ^b   Mashiba, Tasuku ^b   Westmore, Michael S ^c   Ma, Linda ^c  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b KAGAWA UNIVERSITY   (Japan)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 73649104485     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-540-45456-4_35     Document Type: Chapter

References (26)

1. Bergstrom JD, Bostedor RG, Masarachia P.J. (2000) Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 373:231-241
2. Black DM, Cummings SR, Karpf D.B., Cauley JA, Tompson DE, Nevitt MC, Bauer D.C., Genant HK, Haskell WL, Marcus R, Ott S.M., Torner JC, Quandt SA, Reiss TF, Ensrud K.E. (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541
3. Cao YP, Mori S, Mashiba T.K., Westmore MS, Ma L, Sato M, Akiyama T., Shi LP, Komatsubara S, Miyamoto K, Norimatsu H. (2002) Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res 17:2237-2246
4. Chao EY, Inoue N, Elias J.J., Aro H. (1998) Enhancement of fracture healing by mechanical and surgical intervention. Clin Orthop 355 (Suppl):S163-S178
5. Delmas PD, Bjarnason NH, Mitlak B.H., Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C. (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641-1647
6. Devogelaer JP, Broll H, Correa-Rotter R, Cumming D.C., De Deuxchaisnes CN, Geusens P, Hosking D, Jaeger P., Kaufman JM, Leite M, Leon J, Liberman U., Menkes CJ, Meunier PJ, Reid I, Rodriguez J., Romanowicz A, Seeman E, Vermeulen A., Hirsch LJ, Lombardi A, Plezia K, Santora A.C., Yates AJ, Yuan W (1996) Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 18:141-150
7. Ettinger B, Black DM, Mitlak B.H., Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas P.D., Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen F.J., Eckert S., Ensrud KE, Avioli LV, Lips P, Cummings S.R. (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. J Am Med Assoc 282:637-645
8. Fleisch H (2001) Can bisphosphonates be given to patients with fractures? J Bone Miner Res 16:437-440
9. Fisher JE, Rodan GA, Reszka A.A. (2000) In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinol 141:4793-4796
10. Grese TA, Dodge J.A. (1998) Selective estrogen receptor modulators (SERMs). Curr Pharm Des 4:71-92
11. Hyvonen PM, Karhi T, Kosma V.M. (1994) The influence of dichloromethylene bisphosphonate on the healing of a long bone fracture, composition of bone mineral and histology of bone in the rat. Pharmacol Toxicol 75:384-390
12. Lenehan TM, Balligand M, Nunamaker D.M. (1985) Effect of EHDP on fracture healing in dogs. J Orthop Res 3:499-507
13. Li J, Mori S, Kaji Y., Mashiba T, Kawanishi J, Norimatsu H. (1999) Effect of bisphosphonate (incadronate) on fracture healing of long bones in rats. J Bone Miner Res 14:969-979
14. Li J, Mori S, Kaji Y., Kawanishi J, Akiyama T, Norimatsu H. (2000) Concentration of bisphosphonate (incadronate) in callus area and its effects on fracture healing in rats. J Bone Miner Res 15:2042-2051
15. Li C, Mori S, Li J., Kaji Y, Akiyama T, Kawanishi J., Norimatsu H. (2001) Long-term effect of incadronate disodium (YM-175) on fracture healing of femoral shaf in growing rats. J Bone Miner Res 16:429-436
16. Liberman UA, Weiss SR, Broll J, Minne H.W., Quan H., Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M. (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437-1443
17. Monaghan BA, Kaplan FS, Lyttle C.R., Fallon MD, Boden SD, Haddad J.G. (1992) Estrogen receptors in fracture healing. Clin Orthop 280:277-280
18. Nakamura T, Hara Y, Tagawa M., Tamura M, Yuge T, Fukuda H., Nigi H. (1998) Recombinant human basic fibroblast growth factor accelerates fracture healing by enhancing callus remodeling in experimental dog tibial fracture. J Bone Miner Res 13:942-949
19. Nyman MT, Paavolainen P, Lindholm T.S. (1993) Clodronate increases the calcium content in fracture callus. An experimental study in rats. Arch Orthop Trauma Surg 112:228-231
20. Odvina CV, Zerwekh JE, Rao DS et al. (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294-1301
21. Peter CP, Cook WO, Nunamaker D.M., Provost MT, Seedor JG, Rodan G.A. (1996) Effect of alendronate on fracture healing and bone remodeling in dogs. J Orthop Res 14:74-79
22. Pizones J, Plotkin H, Parra-Garcia JI et al. (2005) Bone healing in children with osteogenesis imperfecta treated with bisphosphonates. J Pediatr Orthop 25:332-335
23. Rodan GA, Fleisch H.A. (1996) Bisphosphonates: mechanisms of action. J Clin Invest 97:2692-2696
24. Russell RG, Rogers M.J. (1999) Bisphosphonate: from the lab oratory to the clinic and back again. Bone 25:97-106
25. Sato M, Grese TA, Dodge J.A., Bryant HU, Turner C.H. (1999) Emerging therapies for the prevention or treatment of postmenopausal osteoporosis. J Med Chem 42:1-24
26. Van der Poest Clement E, Patka P, Vandormael K, Haarman H, Lips P (2000) The effect of alendronate on bone mass afer distal forearm fracture. J Bone Miner Res 15:586-593